Moreover, we noted a dose-response relation with a higher cut-off improving survival in PD-L1 positive NSCLC patients (HR1% 0.72 vs. HR5% 0.63 vs. HR10% 0.43vs. This evidence concerns the gene CD274 and non-small cell lung carcinoma.